Top Markets
#1 Pleasing Gold Pleasing Gold +1,498.45%
#2 Ontology Gas Ontology Gas +151.18%
#3 PulseChain PulseChain +57.64%
#4 ConstitutionDAO ConstitutionDAO +37.98%
#5 BOOK OF MEME BOOK OF MEME +31.10%
#6 Neiro Neiro +29.12%
#7 Collect on Fanable Collect on Fanable +28.84%
#8 Pump.fun Pump.fun +27.30%
#9 Unit Pump Unit Pump +27.30%
#10 Ontology Ontology +27.09%
Coin of the day
Pleasing Gold Pleasing Gold
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
LAVA Therapeutics N.V. LAVA Therapeutics N.V.

LAVA Therapeutics N.V.

LVTX
Classifica tra le azioni #25846
LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical... LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer. Utilizing its proprietary Gammabody platform, the company engineers innovative bispecific antibodies. These antibodies are specifically designed to engage and harness the potent and precise capabilities of gamma delta T cells, aiming to stimulate a robust anti-tumor immune response and ultimately enhance outcomes for individuals battling cancer. Key compounds in its clinical pipeline include LAVA-051, currently undergoing Phase 1/2a trials for various hematologic malignancies such as chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. Another front-runner, LAVA-1207, is also in Phase 1/2a clinical studies, targeting metastatic castration-resistant prostate cancer. Furthermore, LAVA Therapeutics is advancing additional Gammabody candidates: LAVA-1223, an investigational treatment for specific solid tumors that targets the epidermal growth factor receptor (EGFR), and preclinical assets LAVA-1266 and LAVA-1278, intended for a range of blood cancers. The company has also forged a research collaboration and licensing partnership with Janssen Biotech, Inc. This alliance focuses on the potential discovery and development of multi-specific antibody therapies aimed at a particular target across diverse therapeutic applications. Established in 2016, LAVA Therapeutics N.V. operates from its headquarters in Utrecht, the Netherlands.
Prezzo delle azioni
$1.74
Ultima sincronizzazione: 2025-11-28
Capitalizzazione di mercato
$45.77M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
13.73%
Paese
NL
Scambia LAVA Therapeutics N.V. (LVTX)

Categoria

Healthcare
Rapporto P/S per LAVA Therapeutics N.V. (LVTX)
Rapporto P/S al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di LAVA Therapeutics N.V., il rapporto P/S attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per LAVA Therapeutics N.V. da 2026 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
Non abbastanza dati per le date fornite.
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US